AstraZeneca Opts Out Of Targacept Schizophrenia Program
This article was originally published in The Pink Sheet Daily
Targacept says it will continue to develop its schizophrenia drug, even though AstraZeneca has opted not to move forward.
You may also be interested in...
Neuroscience track at the Therapeutic Area Partnerships conferencewill feature novel candidates for Alzheimer’s, depression, traumatic brain injury, Fragile X syndrome and post-herpetic neuralgia.
In light of rumors that Bristol-Myers Squibb is looking to buy a major biopharma, DOTW evaluates the role deal-making has played in the company’s rebuilding since it implemented its “string-of-pearls” strategy in 2007. Plus updates on Celgene/Presage, Array/Global Blood Therapeutics, Targacept/AstraZeneca and more.
The termination of a Phase III trial for Abbott/Reata’s projected blockbuster bardoxolone is just one of several recent major blow-ups of a significant pharma/biotech collaboration. One analyst thinks narrow, short-term thinking by business development execs links all of the clinical letdowns.